Text Size

Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients

This study has been completed.
Sponsor:
Collaborator:
BioGaia AB
Information provided by (Responsible Party):
Moahmed Hassan Emara, Zagazig University
ClinicalTrials.gov Identifier:
NCT01593592
First received: May 5, 2012
Last updated: February 2, 2013
Last verified: February 2013
History of Changes
  Purpose

Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.


Condition Intervention
Helicobacter Pylori Infection
 Dietary Supplement: Lactobacillus reuteri
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients: a Double Blind Placebo Controlled Randomized Clinical Trial

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Zagazig University:

Primary Outcome Measures:
  • Assess reduction of H Pylori infection 4 weeks from introduction of therapy [ Time Frame: 4 weeks therapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Development of severe adverse effects to the used medications and dietary supplements. [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 70
Study Start Date: June 2012
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lactobacillus reuteri group
The active group that will receive the standard triple therapy and Lactobacillus reuteri
 Dietary Supplement: Lactobacillus reuteri
Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
Placebo Comparator: Control group
The control group that will receive the standard triple therapy and placebo
 Dietary Supplement: Placebo
Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.

Detailed Description:

Helicobacter pylori (H. Pylori) infection is a wide spread disease and is endemic in many countries including Egypt with a wide range of morbidity; that requires appropriate antimicrobial therapy . However, worldwide the eradication rate following the standard triple therapy is declining and this may necessitates introduction of new antimicrobial agents . On the sight of bearing in vivo and in vitro activity against H. Pylori, the use of different strains of probiotics in treatment of H. Pylori may be thus justifiable, Lactobacillus reuteri (L. reuteri) which through different mechanisms including production of reuterin have anti H.pylori activity have been tried in improving the eradication rates of H.pylori with contradictory results . This study is conducted to test the assumption that addition of L. reuteri to the standard triple therapy in treatment of H. Pylori improves the eradication rates and clinical aspects in H. Pylori infection.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion of patients with these criteria

  1. Age: 18-60 years
  2. Any sex
  3. Confirmed H. Pylori infection defined by pathological lesions and either histopathological confirmation of the organism, rapid urease test or H. Pylori antigen in stool
  4. Good mentality to understand aim, benefits and steps of the study
  5. Assumed availability during the study period
  6. Written informed consent

Exclusion Criteria:

  • Exclusion of

    1. Patients with chronic diseases e.g. diabetes, renal failure, cirrhosis…etc.
    2. Patients with malignancy.
    3. Patients with gall bladder disorders.
    4. Patients with peptic ulcer.
    5. Patients with prior upper GIT surgery.
    6. Patients with probiotics therapy in the last one month.
    7. Patients with triple therapy, antibiotics, proton pump inhibitors and H2 receptor blockers therapy within one month.

    8. Patients with known allergy to the used medications

      -

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01593592

Locations
Egypt
Zagazig University Hospitals
Zagazig, Sharkia, Egypt, 44519
Sponsors and Collaborators
Zagazig University
BioGaia AB
  More Information

Additional Information:
Study location Hospital  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Moahmed Hassan Emara, Lecturer of Tropical Medicine and Hepatogastroenterology, Zagazig University
ClinicalTrials.gov Identifier: NCT01593592     History of Changes
Other Study ID Numbers: IRB#:395/29-4-2012, IRB#:395/29-4-2012
Study First Received: May 5, 2012
Last Updated: February 2, 2013
Health Authority: Egypt: Zagazig University

Keywords provided by Zagazig University:
Helicobacter pylori
Lactobacillus reuteri
dyspeptic patients
eradication

Additional relevant MeSH terms:
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on May 21, 2013